Ewing Sarcoma - Pipeline Insight, 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Feb 1, 2019--The “Ewing Sarcoma - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Ewing Sarcoma - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Ewing Sarcoma development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:Clinical Non-clinical Inactive: Discontinued and/or Dormant
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Scope of the ReportThe report provides a snapshot of the pipeline development for the Ewing Sarcoma The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Ewing Sarcoma The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Ewing Sarcoma The report also covers the dormant and discontinued pipeline projects related to Ewing Sarcoma
Reasons to BuyEstablish comprehensive understanding of the pipeline activity across this Ewing Sarcoma to formulate effective R&D strategies Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Ewing Sarcoma therapeutics Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress
1. Report Introduction
2. Ewing Sarcoma Overview
3. Pipeline TherapeuticsAn Overview of Pipeline Products for Ewing Sarcoma
4. Comparative Analysis
5. Products in Clinical StageProduct Description Research and Development Product Development Activities
6. Products in Pre-Clinical and Discovery StageProduct Description Research and Development Product Development Activities
7. Therapeutic AssessmentAssessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type
8. Inactive ProductsProduct Description Research and Development Product Development Activities
Companies FeaturedCBT Pharmaceuticals Inc. Celgene Corp. Celldex Therapeutics Inc. Cellectar Biosciences Inc. CellSeed Inc. Clovis Oncology Inc. Cyclacel Pharmaceuticals Inc. Eli Lilly and Company F. Hoffmann-La Roche Ltd. Amgen Astellas Bristol-Myers Cebiotex Celgene Celldex CytRx
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/k9vgj5/ewing_sarcoma?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190201005271/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Oncology Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 02/01/2019 08:43 AM/DISC: 02/01/2019 08:43 AM